Published: 28 September 2022
Author(s): Marcello Di Nisio, Nicola Potere, Ettore Porreca
Section: Commentary

Venous thromboembolism (VTE) represents a relatively common complication in patients with cancer and is associated with considerable morbidity and mortality as well as resources utilization and health care costs. Cancer confers a 12-fold higher risk of developing VTE within the first 6 months after diagnosis, which is further augmented up to 23-fold during chemotherapy or targeted anti-cancer therapy [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.